RDC-Blinatumomab Versus hyperCVAD for Ph-negative B-ALL.

PHASE2RecruitingINTERVENTIONAL

Enrollment

124

Participants

Timeline

Start Date

February 5, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions

ALL, AdultPhiladelphia-Negative ALL

Interventions

DRUG

Blinatumomab Injection [Blincyto]

Reduced-intensity chemotherapy followed by Blinatumomab

DRUG

Doxorubicin

HyperCVAD regimen

Trial Locations (1)

RECRUITING

The First Affiliated Hospital of Soochow University, Suzhou

All Listed Sponsors

lead

Chen Suning

OTHER